MOTS-c: Mitochondrial-Derived Peptide for Metabolic Homeostasis Research

What Is MOTS-c?

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16-amino-acid peptide encoded within the mitochondrial genome. With a molecular weight of approximately 2175 Da, MOTS-c is unique among research peptides because it is encoded by mitochondrial DNA rather than nuclear DNA. Its discovery in 2015 by Lee et al. at USC opened a new chapter in understanding mitochondria as active signaling organelles that produce regulatory peptides — termed mitochondrial-derived peptides (MDPs).

For dosing, reconstitution, and protocol details, see our MOTS-c Dosage Protocol Guide: Reconstitution, Research Dosing & Metabolic Research (2026).

The 16-amino acid sequence of MOTS-c is MRWQEMGYIFYPRKLR, encoded by a short open reading frame (sORF) within the 12S ribosomal RNA gene of the mitochondrial genome. This discovery challenged the long-held assumption that mitochondrial ribosomes only translated the 13 proteins encoded by the classic mitochondrial ORFs. MOTS-c represents a new class of bioactive molecules that emerge from a previously overlooked region of the mitochondrial genome.

Discovery and Significance

The 2015 discovery of MOTS-c by Lee et al. in Cell Metabolism fundamentally changed perspectives on mitochondrial biology (Lee et al., Cell Metab 2015). Prior to this work, the mitochondrial genome was thought to encode only 13 proteins (all electron transport chain components), 22 tRNAs, and 2 rRNAs. The identification of functional sORFs within previously non-coding regions established a new paradigm of "mitochondrial-nuclear communication" through bioactive peptides.

MOTS-c is now understood as part of a larger family of mitochondrial-derived peptides that includes humanin (discovered in 2001) and SHLP1-6 (identified 2016). However, MOTS-c has attracted exceptional research attention due to its:

• •Translocability to the nucleus in response to metabolic stress
• •Regulation of AMPK and insulin signaling pathways
• •Exercise-mimicking metabolic effects
• •Age-dependent decline mirroring age-related metabolic deterioration

Molecular Biology

Mitochondrial Genome Origin

MOTS-c is encoded within the 12S ribosomal RNA (rRNA) sequence in the mitochondrial genome — a region previously considered exclusively structural (part of the small ribosomal subunit). The open reading frame is 51 nucleotides, encoding the 16-amino acid peptide. The existence of functional sORFs within rRNA-designated sequences of the mitochondrial genome suggests that mitochondrial genomic complexity is greater than previously recognized.

Subcellular Trafficking

One of the most scientifically remarkable features of MOTS-c is its capacity for subcellular translocation. MOTS-c is synthesized in the mitochondrial matrix, but under conditions of metabolic stress or exercise, it translocates from mitochondria to the nucleus. In the nucleus, MOTS-c acts as a transcriptional regulator, binding directly to DNA response elements and regulating gene expression — a previously undescribed mode of peptide action.

This mitochondria-to-nucleus translocation is activated by:

• •Glucose restriction and fasting
• •High-intensity exercise
• •Oxidative stress
• •Metformin treatment
• •Heat stress

The nuclear translocation mechanism provides MOTS-c a direct pathway to reprogram gene expression in response to energetic challenges, establishing it as a mitochondrial retrograde signal that coordinates cellular adaptation to metabolic demands.

Mechanism of Action

AMPK Activation

MOTS-c's primary identified mechanism involves activation of AMP-activated protein kinase (AMPK) — often called the "master regulator of cellular energy homeostasis." AMPK is activated when cellular ATP-to-AMP ratios decrease (indicating energy deficit) and triggers adaptive responses including:

• •Increased glucose uptake and glycolysis
• •Enhanced fatty acid oxidation
• •Suppression of energy-consuming anabolic processes
• •Mitochondrial biogenesis

MOTS-c activates AMPK by targeting the folate cycle — specifically through inhibition of ATIC (AICAR transformylase), which increases cellular AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) levels. AICAR is a pharmacological AMPK activator, and MOTS-c mimics its effect by promoting endogenous AICAR accumulation (Lee et al., Cell Metab 2015).

Insulin Sensitization

MOTS-c administration in insulin-resistant research models produces robust improvements in insulin sensitivity. The mechanism involves AMPK-mediated enhancement of:

• •GLUT4 translocation to the plasma membrane (increasing glucose uptake)
• •Insulin receptor signaling cascade (IRS-1, PI3K, Akt phosphorylation)
• •Suppression of fatty acid-induced insulin resistance in skeletal muscle

In high-fat diet rodent models, MOTS-c administration has been shown to:

• •Reduce fasting blood glucose by 40-60%
• •Improve glucose tolerance test performance
• •Reduce insulin resistance (HOMA-IR improvement)
• •Decrease ectopic fat accumulation in liver and muscle

These findings position MOTS-c as a research tool for studying metabolic disease mechanisms and potential intervention strategies.

Nuclear Function: Gene Regulation

Upon stress-induced nuclear translocation, MOTS-c binds to antioxidant response elements (ARE) in the promoters of stress-response genes. This direct transcription factor-like activity allows MOTS-c to upregulate cytoprotective gene programs including:

• •Nrf2 target genes (NQO1, GCLC, HMOX1)
• •Adaptive stress-response genes
• •Mitochondrial biogenesis regulators (PGC-1α target genes)

This transcriptional activity represents a new paradigm — a mitochondrially-encoded peptide functioning as a nuclear transcription regulator — with significant implications for understanding how mitochondrial stress is communicated to the nucleus.

Reactive Oxygen Species (ROS) Management

MOTS-c influences cellular redox balance through multiple mechanisms:

• •Direct activation of Nrf2-dependent antioxidant gene programs (through ARE binding in the nucleus)
• •AMPK-mediated reduction of mitochondrial ROS generation
• •Enhancement of mitochondrial uncoupling as a ROS-dissipation mechanism
• •Modulation of peroxisome proliferator-activated receptor (PPAR) pathways involved in lipid oxidation

The net effect is a reduction in oxidative stress burden and improvement in cellular redox homeostasis, which may contribute to the longevity-associated effects observed in some aging models.

Research Applications

Metabolic Disease and Obesity Research

MOTS-c's insulin-sensitizing and AMPK-activating properties make it a highly relevant research tool for metabolic disease models:

Type 2 Diabetes Models: In diet-induced obesity (DIO) and genetic obesity models, MOTS-c administration improves all major metabolic parameters. Research studies have demonstrated that MOTS-c can reverse established insulin resistance, not just prevent its development, making it of interest as a potential intervention tool.

Adiposity and Body Composition: MOTS-c treatment in obese rodent models reduces adiposity through enhanced fatty acid oxidation and possible effects on adipogenesis. These effects are distinct from those observed with simple caloric restriction, suggesting MOTS-c activates specific anti-obesity programs rather than simply reducing appetite.

Non-Alcoholic Fatty Liver Disease (NAFLD): High-fat diet models treated with MOTS-c show reduced hepatic lipid accumulation and improved liver function markers, addressing the hepatic component of metabolic syndrome.

Exercise Physiology Research

Perhaps the most intriguing research application of MOTS-c is as an "exercise mimetic" — a compound that activates molecular pathways normally activated by physical activity. Exercise is the most powerful physiological activator of AMPK, and MOTS-c replicates many of exercise's downstream effects:

• •Enhanced mitochondrial biogenesis (PGC-1α upregulation)
• •Increased GLUT4 expression in skeletal muscle
• •Improved insulin sensitivity
• •Reduction in hepatic gluconeogenesis
• •Anti-obesity and body composition improvements

Research has also shown that exercise itself increases circulating MOTS-c levels in humans, suggesting MOTS-c may mediate some of exercise's systemic metabolic benefits. A 2021 study demonstrated that MOTS-c levels rise during exercise and that elevated MOTS-c contributes to exercise-induced AMPK activation in skeletal muscle.

This bidirectional relationship — exercise induces MOTS-c release, and MOTS-c mediates exercise adaptations — positions MOTS-c as a key mediator of exercise's health benefits and a potential replacement or supplement for exercise in research contexts studying metabolic adaptation.

Aging and Longevity Research

MOTS-c levels decline with age in both rodent models and human studies, paralleling the metabolic deterioration associated with aging. This age-related decline is hypothesized to contribute to:

• •Age-related insulin resistance and type 2 diabetes risk
• •Loss of metabolic flexibility (reduced ability to switch between fuel sources)
• •Mitochondrial dysfunction in aging
• •Reduced stress resilience at the cellular level

Research in aged rodent models demonstrates that MOTS-c supplementation can partially reverse metabolic aging phenotypes. Notably, MOTS-c extends lifespan in some invertebrate models (C. elegans and Drosophila), though translation to mammals requires further study.

Human data shows that MOTS-c levels correlate with metabolic health markers and decline with age, supporting its potential role as a biomarker of metabolic aging.

Exercise-Independent AMPK Research

MOTS-c provides a valuable research tool for studying AMPK biology specifically through the folate cycle mechanism, distinct from other AMPK activators like AICAR, metformin, or 2-DG. This mechanistic specificity allows researchers to:

• •Dissect folate cycle contributions to AMPK regulation
• •Compare MOTS-c with other AMPK activators for pathway-specific effects
• •Study the metabolic consequences of AMPK activation without direct mitochondrial complex I inhibition (metformin's mechanism)

Mitochondria-Nucleus Crosstalk

MOTS-c's nuclear translocation represents a model system for studying mitochondria-to-nucleus retrograde signaling — how mitochondria communicate their functional state to the nucleus to reprogram gene expression. Research applications include:

• •Characterizing the molecular signals that trigger MOTS-c nuclear import
• •Identifying ARE sequences and nuclear binding partners of MOTS-c
• •Mapping the gene expression programs regulated by nuclear MOTS-c
• •Understanding how mitochondrial stress activates cytoprotective nuclear gene programs

Pharmacokinetics and Tissue Distribution

Systemic Distribution

Following subcutaneous or intraperitoneal administration in research models, MOTS-c achieves broad tissue distribution including:

• •Skeletal muscle (primary metabolic target)
• •Liver (adipogenesis and gluconeogenesis regulation)
• •Adipose tissue (lipolysis and adipogenesis effects)
• •Brain (emerging neuroactive roles)
• •Circulation (acts as an endocrine signal)

Endocrine Properties

MOTS-c functions as an endocrine hormone — released by mitochondria in one tissue, it travels through the bloodstream to exert effects in distant tissues. This endocrine mode of action distinguishes MOTS-c from locally-acting paracrine or autocrine signals and suggests potential for systemic therapeutic applications in metabolic diseases.

Exercise-induced increases in circulating MOTS-c in humans represent a physiological model of endocrine MOTS-c signaling, supporting the relevance of exogenous MOTS-c administration as a research strategy.

Species Conservation and Human Relevance

A notable feature of MOTS-c is that its sequence is highly conserved across mammals, suggesting evolutionary conservation of its function. The human, murine, and primate sequences show >90% identity, supporting translational relevance of rodent research findings to human biology.

However, a known variant in the MOTS-c-encoding mitochondrial locus has been identified in East Asian populations (K14Q variant) that shows different biological activity. Research into MOTS-c variants and their metabolic consequences is an active area of investigation with implications for population-specific metabolic risk.

Comparison with Related Compounds

MOTS-c vs. Humanin

Humanin is the best-characterized mitochondrial-derived peptide and shares the MDP classification with MOTS-c:

MOTS-c vs. Metformin

MOTS-c and metformin both activate AMPK, but through different mechanisms with different metabolic profiles:

Research Specifications

• •Molecular weight: 2174.67 Da
• •Molecular formula: C₉₅H₁₆₁N₃₃O₂₃S
• •Sequence: MRWQEMGYIFYPRKLR
• •CAS number: 1457006-04-0
• •Length: 16 amino acids
• •Administration route: Subcutaneous (primarily in research models)
• •Available forms: Lyophilized powder
• •Reconstitution: Sterile water (typically 1 mg/mL stock)
• •Storage: -20°C (lyophilized), 2-8°C (reconstituted)
• •Classification: For laboratory research use only (RUO)

Related Research Compounds

Researchers studying metabolic pathways, mitochondrial function, or aging alongside MOTS-c may find value in exploring:

• •NAD+ — metabolic coenzyme working in converging pathways with MOTS-c on mitochondrial function and aging
• •Methylene Blue — electron carrier with mitochondrial enhancing properties
• •AICAR (Acadesine) — small-molecule AMPK activator and exercise mimetic sharing MOTS-c's downstream signaling axis
• •SS-31 (Elamipretide) — mitochondria-targeted tetrapeptide studied alongside MOTS-c in bioenergetic research

The discovery of MOTS-c represents a paradigm shift in our understanding of mitochondrial biology and intercellular communication, establishing mitochondria as active endocrine organs whose peptide products coordinate systemic metabolic responses to energy demands.

MOTS-c in Exercise and Aging Research: Expanded Mechanistic Perspective

MOTS-c's emergence as a "mitochondrial hormone" represents a conceptual shift in how researchers understand mitochondrial-nuclear communication — moving from a model where mitochondria are passive energy producers to one where they actively signal cellular and systemic states through secreted peptides.

The Retrograde Signaling Framework

MOTS-c is encoded in mitochondrial 12S rRNA and is translated by mitochondrial ribosomes. Unlike the vast majority of mitochondrial proteins (which are encoded by nuclear DNA and imported into mitochondria), MOTS-c moves in the opposite direction: synthesized in mitochondria, it translocates to the nucleus to regulate gene expression. This retrograde signaling capacity places MOTS-c at the intersection of three critical research areas:

1. Mitochondria-nucleus crosstalk: How mitochondrial metabolic state communicates to the nucleus to coordinate adaptive gene expression

2. Exercise adaptation biology: MOTS-c is released during exercise in proportion to intensity, potentially acting as an exercise mimetic at the molecular level

3. Aging and metabolic resilience: MOTS-c levels decline with age in rodents and humans, paralleling the age-related loss of metabolic flexibility and exercise capacity

MOTS-c and the Exercise Mimetic Concept

The observation that MOTS-c increases in blood and muscle during aerobic exercise in both rodents and humans has generated interest in MOTS-c as a potential "exercise in a bottle" research tool. The mechanistic basis for this interest is substantive:

• •AMPK activation: MOTS-c activates AMP-activated protein kinase (AMPK), the master regulator of cellular energy sensing, through a mechanism involving AICAR-like intermediates in the folate cycle
• •PGC-1α induction: Downstream of AMPK, MOTS-c promotes expression of PGC-1α, the primary transcriptional coactivator for mitochondrial biogenesis — the same pathway activated by endurance exercise
• •Fatty acid oxidation: MOTS-c increases expression of genes in the fatty acid β-oxidation pathway, shifting fuel preference away from glucose, replicating a key metabolic adaptation of exercise-trained muscle

Notably, the MOTS-c/AMPK/PGC-1α axis appears to function in a tissue-autonomous manner in skeletal muscle, meaning that injected MOTS-c can activate these pathways in muscle independent of systemic hormonal or neural signals. This makes MOTS-c valuable for mechanistic studies isolating mitochondrial-nuclear communication from whole-organism exercise responses.

Age-Related MOTS-c Decline and Intervention Research

Circulating MOTS-c levels decline significantly with age in both preclinical and human data, leading researchers to characterize it as part of the broader mitokine decline that accompanies aging. Key findings in this area:

• •Kim et al. (2018, Cell Metabolism) demonstrated that circulating MOTS-c decreases by ~50% in aged mice (24 months) compared to young mice (6 months), and that exogenous MOTS-c administration in aged mice improved physical performance, insulin sensitivity, and energy metabolism toward younger baseline values
• •Human studies have shown a positive correlation between circulating MOTS-c and muscle mass/performance in elderly cohorts, raising the question of whether MOTS-c decline contributes causally to sarcopenic metabolic dysfunction
• •Interaction with sex hormones: MOTS-c levels are influenced by androgenic signaling — testosterone increases MOTS-c production in some preclinical models, which may partly explain sex differences in the rate of age-related metabolic decline

MOTS-c in Nuclear Stress Response Research

A distinct function of MOTS-c discovered in later research is its nuclear translocation under stress conditions to regulate expression of antioxidant genes and stress response pathways. This nuclear function is activated by specific conditions (reactive oxygen species, metabolic stress) that cause MOTS-c to translocate from the cytoplasm to the nucleus, where it associates with the antioxidant response element (ARE) transcription factor Nrf2 among others.

This dual cytoplasmic/nuclear biology makes MOTS-c experimentally unusual: depending on the stress state of the cell, the same peptide can function as either a metabolic activator (AMPK pathway, cytoplasmic) or a transcriptional stress responder (nuclear). Researchers designing cell culture experiments should control for basal oxidative stress in their cell lines, as this may shift the predominant MOTS-c mechanism being studied.

MOTS-c vs. SS-31 and Humanin: A Three-Way Mitochondrial Peptide Comparison

This comparison illustrates why the three peptides serve complementary rather than redundant research functions: MOTS-c addresses systemic metabolic and exercise biology, SS-31 addresses organelle-level membrane integrity, and Humanin addresses cytoprotective signaling. See the full comparison in the Mitochondrial Peptides Compared guide.

MOTS-c Supplier Pricing Comparison (Live Data — August 2026)

Peptides.SO tracks 144+ in-stock listings for MOTS-c across verified research suppliers as of August 2026, making it one of the more widely available mitochondrial-derived peptides for research.

> Data sourced from Peptides.SO live listings (August 2026). Prices subject to change. 144+ in-stock listings tracked. All products for Research Use Only.

Sourcing notes for MOTS-c:

• •MOTS-c is a 21-amino-acid peptide (MW ~2,174 Da); confirm sequence MRWQEMGYIFYPRKLR with the supplier CoA
• •Per-mg cost range (~$0.39–$4.00/mg for in-stock items) is competitive for a research-grade 21-mer peptide
• •HPLC purity ≥98% and mass spec (ESI-MS or MALDI) confirming the correct MW are standard quality benchmarks for rigorous research use
• •Peptide Stack Builder — combine MOTS-c with Humanin or SS-31 for comparative mitochondrial peptide research protocols
• •Real-time pricing and stock: MOTS-c peptide page

Where to Buy MOTS-c for Research: 2026 Supplier Pricing

MOTS-c is available from multiple research peptide suppliers. Peptides.SO currently tracks 146 active listings across suppliers, with 145 in stock as of September 2026. Pricing varies considerably by vendor — the table below reflects real-time data from our supplier database.

MOTS-c Supplier Pricing Comparison (September 2026)

Source: Peptides.SO supplier database, September 2026. Prices reflect per-mg cost for standard vial sizes. Full listings, stock status, and COA availability at MOTS-c compound page.

Market range: $0.39–$4.75/mg across 146 tracked listings. The 10-fold price spread across suppliers reflects differences in vial size, quantity discounts, and supplier tier rather than purity differences — HPLC ≥98% is the research standard regardless of price point.

What to Verify Before Purchasing Research-Grade MOTS-c

MOTS-c is a 16-amino-acid peptide (MW ~2175 Da, sequence: MRWQEMGYIFYPRKLR). Given this relatively small size, quality verification is straightforward:

1. Molecular weight confirmation — MW 2174.6 Da by LCMS or MALDI-TOF. This is the fastest check to confirm you have the correct peptide, not a truncation or related analog.

2. HPLC purity — ≥98% area under curve at 214 or 220nm. MOTS-c's small size makes impurity peaks easy to identify in a well-run chromatogram.

3. Sequence identity — Some suppliers provide MS/MS fragmentation confirming the full 16-amino-acid sequence. Prefer suppliers who can provide this for in vivo research models.

4. Endotoxin testing — Critical for cell culture and animal models where inflammatory baseline confounds metabolic readouts.

See How to Read a Peptide COA for a detailed walkthrough of what documentation to request and how to interpret each test result. The Peptide Purity Testing guide covers HPLC and mass spectrometry methods in depth.

Related compound pages: MOTS-c listings and pricing · Humanin (MDP family comparison) · SS-31 / Elamipretide (mitochondria-targeted peptide)

Frequently Asked Questions

Is MOTS-c naturally produced by exercise, or is it only relevant when administered exogenously?

Both. MOTS-c is an endogenous mitochondrial-derived peptide, and Reynolds et al. (2021, Nature Communications) showed it is induced by exercise in skeletal muscle in both mice and humans — meaning circulating MOTS-c rises as part of the natural physiological response to exercise. The same study found that exogenous MOTS-c administration enhances physical performance and mitigates age-related physical decline in mouse models, which is why it is studied both as an exercise biomarker and as a standalone research compound.

What is the mechanistic link between MOTS-c and mitochondrial bioenergetics?

A 2026 study in Free Radical Biology and Medicine (Gudiksen et al.) found that MOTS-c administration improved intrinsic skeletal-muscle mitochondrial bioenergetic efficiency in mice, and that this effect was dependent on PGC-1α and AMPK signaling — the same pathways implicated in exercise-induced mitochondrial biogenesis. This gives MOTS-c research a direct mechanistic tie to the AMPK activation already characterized in earlier work.

How does MOTS-c relate to adiponectin and insulin-sensitivity research?

Guo et al. (2020, Diabetologia) found that in mice, adiponectin treatment improved insulin resistance partly by upregulating MOTS-c expression and its exercise responsiveness through the APPL1-SIRT1-PGC-1α pathway. This connects MOTS-c to the broader adipokine-mitochondrial signaling network studied in metabolic disease research, rather than positioning it as an isolated peptide.

How does MOTS-c compare mechanistically to metformin or AICAR as an AMPK-pathway research tool?

MOTS-c activates AMPK through a distinct route from small-molecule AMPK activators: metformin acts primarily via complex I inhibition, and AICAR works through folate-cycle-mediated AICAR/ZMP accumulation, while MOTS-c is a peptide with direct nuclear translocation capability and cytoprotective (rather than inhibitory) mitochondrial effects. Researchers studying AMPK pathway convergence often use these three tools together to dissect which downstream effects are AMPK-pathway-general versus specific to MOTS-c's peptide biology.

What reconstitution and storage practices are standard for MOTS-c research?

MOTS-c is typically reconstituted in sterile water at approximately 1 mg/mL stock concentration and administered subcutaneously in research models. Lyophilized powder should be stored at -20°C; reconstituted solution should be kept at 2-8°C and used within the timeframe validated by the supplier's stability data.

Does MOTS-c cross-react or share pathways with other mitochondrial-derived peptides like humanin?

No direct cross-reactivity, but they are frequently studied together as part of the same mitochondrial-derived-peptide (MDP) family. Both originate from the mitochondrial genome and have cytoprotective properties, but MOTS-c signals primarily through AMPK/nuclear gene regulation while humanin acts through distinct anti-apoptotic pathways. See the site's Humanin vs MOTS-c vs SS-31 comparison for a full mechanistic side-by-side.

Q: How is MOTS-c encoded given that mitochondrial DNA has a different genetic code?

MOTS-c is translated from a short open reading frame (sORF) within the 12S rRNA gene of the mitochondrial genome. Mitochondria use a slightly variant genetic code (e.g., UGA encodes tryptophan rather than serving as a stop codon), and MOTS-c's 16-amino-acid sequence is produced using this mtDNA-specific codon usage. Its nuclear-encoded counterpart is not known to exist, making it a bona fide mitochondria-derived peptide (MDP).

Q: What is the proposed mechanism linking MOTS-c to insulin sensitivity?

MOTS-c activates AMPK and downstream signaling that promotes GLUT4 translocation and glucose uptake in skeletal muscle, independent of insulin receptor engagement. It also suppresses the folate-methionine cycle and the hexosamine biosynthetic pathway — two nutrient-sensing routes linked to insulin resistance — by modulating AICAR accumulation, an endogenous AMPK activator.

Q: Does MOTS-c circulate in blood and if so, how is it measured?

Yes — MOTS-c is detectable in human plasma by ELISA. Circulating levels decline with age and are lower in individuals with metabolic disease in several observational studies. Exercise acutely increases plasma MOTS-c. These observations have fueled its characterization as an endocrine MDP, though the cell types that secrete it into circulation and its receptor(s) remain under active investigation.

Q: What peptide stability considerations are relevant for cell culture experiments?

MOTS-c is a linear peptide without disulfide bonds. It is subject to endosomal proteolysis and can be degraded in serum-containing media. Researchers frequently use serum-free or reduced-serum conditions for short-term treatments, or add protease inhibitors to media. Lyophilized peptide should be reconstituted in sterile water or 0.1% BSA in PBS and stored as aliquots at −80 °C to minimize freeze-thaw degradation.

Q: How does MOTS-c compare to Humanin and SS-31 as research tools targeting mitochondria?

MOTS-c primarily targets metabolic and exercise-related pathways (AMPK, folate cycle, insulin sensitivity). Humanin is more focused on cytoprotection and apoptosis suppression (Bax inhibition, IGFBP-3 sequestration, anti-Alzheimer signaling). SS-31 (elamipretide) targets the inner mitochondrial membrane directly, reducing cardiolipin peroxidation and restoring cristae architecture. These mechanistic distinctions make the three peptides complementary rather than redundant as research probes. See the Mitochondrial-Derived Peptides Compared guide for a full mechanistic side-by-side.

Q: Are there validated rodent aging models for MOTS-c injection studies?

Yes — the most-cited in vivo work uses subcutaneous or intraperitoneal injection in aged mice (18–24 months) or diet-induced obesity models. Studies by Lee et al. demonstrated that daily MOTS-c injection in old mice improved grip strength and exercise tolerance. More recent work (Reynolds et al., 2021) demonstrated that MOTS-c acts as an exercise-induced circulating factor and that exogenous administration partially mimics the metabolic benefits of exercise in sedentary aged animals.

---

Key Research Citations

1. Reynolds JC, et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun, 12:470. PMID: 33473109

2. Gudiksen A, et al. (2026). MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. Free Radic Biol Med. PMID: 41520850

3. Guo B, et al. (2020). Adiponectin treatment improves insulin resistance in mice by regulating the expression of the mitochondrial-derived peptide MOTS-c and its response to exercise via APPL1-SIRT1-PGC-1α. Diabetologia, 63(12):2675-2688. PMID: 32880686

---

---

Further Reading:

• •NAD+: Cellular Energy Coenzyme in Aging and Metabolic Research
• •Humanin: The Mitochondrial-Derived Peptide Redefining Cytoprotection Research
• •Apelin Peptides and the APJ Receptor: The Apelinergic System in Cardiovascular, Metabolic, and Aging Research
• •Methylene Blue: Mitochondrial Enhancer for Neuroprotection Research
• •Reconstitution Calculator

2026 Research Update

MOTS-c research expanded substantially in 2025–2026, with two important developments. First, human epidemiological data confirmed earlier observations that circulating MOTS-c levels decline progressively with age in both men and women, with the sharpest decline observed after age 50 — establishing MOTS-c as a bona fide biomarker of mitochondrial aging in humans. Second, a small pilot intervention study in Japan examined exogenous MOTS-c supplementation in older adults with early metabolic dysfunction, reporting preliminary signals of improved insulin sensitivity and physical performance at 12 weeks, though the study lacked a placebo arm and sample size was limited (n=18).

Additionally, the longevity peptide field saw growing interest in MOTS-c's role in stress resilience: mitochondrial stress in C. elegans and murine models triggers MOTS-c release in a manner that upregulates antioxidant gene expression, suggesting MOTS-c may function as part of a broader mitohormetic stress-response system.

Where to Buy MOTS-c for Research: 2026 Supplier Pricing

MOTS-c is available from multiple research peptide suppliers. Peptides.SO currently tracks 146 active listings across suppliers, with 145 in stock as of September 2026. Pricing varies considerably by vendor — the table below reflects real-time data from our supplier database.

MOTS-c Supplier Pricing Comparison (September 2026)

Source: Peptides.SO supplier database, September 2026. Prices reflect per-mg cost for standard vial sizes. Full listings, stock status, and COA availability at MOTS-c compound page.

Market range: $0.39–$4.75/mg across 146 tracked listings. The 10-fold price spread across suppliers reflects differences in vial size, quantity discounts, and supplier tier rather than purity differences — HPLC ≥98% is the research standard regardless of price point.

What to Verify Before Purchasing Research-Grade MOTS-c

MOTS-c is a 16-amino-acid peptide (MW ~2175 Da, sequence: MRWQEMGYIFYPRKLR). Given this relatively small size, quality verification is straightforward:

1. Molecular weight confirmation — MW 2174.6 Da by LCMS or MALDI-TOF. This is the fastest check to confirm you have the correct peptide, not a truncation or related analog.

2. HPLC purity — ≥98% area under curve at 214 or 220nm. MOTS-c's small size makes impurity peaks easy to identify in a well-run chromatogram.

3. Sequence identity — Some suppliers provide MS/MS fragmentation confirming the full 16-amino-acid sequence. Prefer suppliers who can provide this for in vivo research models.

4. Endotoxin testing — Critical for cell culture and animal models where inflammatory baseline confounds metabolic readouts.

See How to Read a Peptide COA for a detailed walkthrough of what documentation to request and how to interpret each test result. The Peptide Purity Testing guide covers HPLC and mass spectrometry methods in depth.

Related compound pages: MOTS-c listings and pricing · Humanin (MDP family comparison) · SS-31 / Elamipretide (mitochondria-targeted peptide)

Frequently Asked Questions

What is MOTS-c and where does it come from?

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16-amino-acid peptide encoded within the mitochondrial genome — specifically, in the 12S ribosomal RNA gene. Unlike nuclear-encoded proteins, MOTS-c is translated in mitochondria and then exported to the cytoplasm and nucleus, where it activates metabolic regulatory pathways. It is classified as a mitokine: a mitochondria-derived signaling molecule that communicates mitochondrial status to other cellular compartments and to distant tissues via the bloodstream.

How does MOTS-c decline with aging?

Studies in humans and animal models consistently show that circulating MOTS-c levels decrease with age. In a landmark 2019 study in Cell Metabolism, MOTS-c levels in Korean centenarians were significantly higher than age-matched controls in their 70s and 80s, suggesting that preserved mitochondrial MOTS-c production may be a feature of exceptional longevity. The mechanism underlying the age-related decline is not fully characterized but likely involves reduced mitochondrial transcriptional activity and declining mitochondrial biogenesis that accompany cellular aging.

Is MOTS-c the same as Humanin?

No — though both are mitochondria-derived peptides (mitokines) encoded in the mitochondrial 12S rRNA gene region. MOTS-c is 16 amino acids and primarily activates AMPK-mediated metabolic regulation and nuclear antioxidant gene programs. Humanin is 21 amino acids and has more prominent neuroprotective and anti-apoptotic functions. The two peptides have partially overlapping but distinct receptor systems and biological targets. Research increasingly treats them as complementary members of a mitochondria-derived signaling family rather than redundant compounds.

Does exercise affect MOTS-c levels?

Yes. Acute exercise increases circulating MOTS-c in animal models, and MOTS-c administration to sedentary animals partially recapitulates metabolic adaptations normally associated with physical training — including improved glucose uptake and mitochondrial gene expression in skeletal muscle. This exercise-mimetic property is one of the most actively studied aspects of MOTS-c biology, with particular relevance to sarcopenia and metabolic disease research in aging populations.

Is MOTS-c FDA approved or in clinical trials?

MOTS-c is not FDA approved and no Phase 3 human clinical trials have been completed as of 2026. Small pilot studies have been conducted in Japan. MOTS-c is classified as an investigational research peptide. All research-grade MOTS-c is sold for laboratory use only under research-use-only (RUO) classification.

What are the main research applications for MOTS-c?

Pre-clinical research has examined MOTS-c in four primary areas: (1) metabolic disease and obesity — improving insulin sensitivity and reducing adiposity in diet-induced obesity models; (2) exercise physiology — replicating some adaptations of aerobic training; (3) aging and longevity — counteracting age-associated metabolic decline; and (4) mitochondrial biology — understanding how mitochondria communicate metabolic status to the nucleus and peripheral organs via peptide signaling.

> Research Use Only Disclaimer: MOTS-c is an investigational peptide. All information in this article is derived from pre-clinical research studies. This content does not constitute medical advice or a treatment recommendation. MOTS-c is not approved for human use by any regulatory authority.